Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Abbott Laboratories ( (ABT) ) has provided an update.
On February 23, 2026, Abbott Laboratories entered into a pricing agreement with a syndicate of major investment banks to issue $20 billion in senior notes across multiple floating- and fixed-rate tranches maturing between 2029 and 2066. The sale of the notes, offered under an effective shelf registration and detailed in a prospectus supplement filed with the SEC, is expected to close on March 9, 2026, subject to customary conditions.
Abbott plans to use the net proceeds from this large-scale debt issuance, together with cash on hand and potential additional borrowings, to fund the purchase price for its acquisition of Exact Sciences, refinance certain Exact Sciences debt, pay related fees and expenses, and for general corporate purposes. The transaction underscores Abbott’s willingness to leverage the debt markets to finance strategic expansion in diagnostics and related healthcare offerings, with implications for its capital structure and future balance sheet flexibility.
The most recent analyst rating on (ABT) stock is a Buy with a $124.00 price target. To see the full list of analyst forecasts on Abbott Laboratories stock, see the ABT Stock Forecast page.
Spark’s Take on ABT Stock
According to Spark, TipRanks’ AI Analyst, ABT is a Neutral.
The score is driven primarily by strong cash flow and solid operating performance, supported by upbeat 2026 guidance and continued momentum in Medical Devices/CGM. These positives are moderated by uncertainty from incomplete 2025 balance sheet data and net-income volatility, while technical indicators remain weak versus longer-term averages and valuation appears relatively rich.
To see Spark’s full report on ABT stock, click here.
More about Abbott Laboratories
Abbott Laboratories is a diversified global healthcare company that develops, manufactures, and markets medical devices, diagnostics, nutritional products, and branded generic pharmaceuticals. The company focuses on chronic disease management, diagnostics, and consumer health, serving hospitals, laboratories, and patients worldwide across developed and emerging markets.
Average Trading Volume: 8,894,129
Technical Sentiment Signal: Hold
Current Market Cap: $199.1B
For detailed information about ABT stock, go to TipRanks’ Stock Analysis page.